搜索
ss
ss
关于普米斯
About Us
918刘晓林

Xiaolin Liu (Chairman)

As Chairman and CEO of Biotheus, Xiaolin has over 20 years of experience in antibody discovery and development. Previously, Xiaolin served in R&D roles at Abbott, Bristol-Myers Squibb and Adimab. In 2012, Xiaolin was appointed as Vice President of R&D at Innovent Biologics where he led an R&D team of more than 100 scientists, and created a product development pipeline of more than 20 novel antibody-based assets. As the project leader, he successfully oversaw the discvoery, development and and launch of Tyvyt (sintilimab) on the Chinese market.
918刘晓林
Product description
Parameters

As Chairman and CEO of Biotheus, Xiaolin has over 20 years of experience in antibody discovery and development. Previously, Xiaolin served in R&D roles at Abbott, Bristol-Myers Squibb and Adimab. In 2012, Xiaolin was appointed as Vice President of R&D at Innovent Biologics where he led an R&D team of more than 100 scientists, and created a product development pipeline of more than 20 novel antibody-based assets. As the project leader, he successfully oversaw the discvoery, development and and launch of Tyvyt (sintilimab) on the Chinese market.

Keyword:
科学
研发
抗体
开发
领导
单抗
产品
新药
团队
20
Scan the QR code to read on your phone
We could not find any corresponding parameters, please add them to the properties table
Previous
There is currently no content to display
Please add data record on website background.

Copyright: © 2021 Biotheus, Inc.     粤ICP备2021122492号      Powered by www.300.cn